Percutaneous transluminal coronary angioplasty in 1980-85 and 1995-96: More frequent multivessel disease, fewer reoperations and no change in mortality 1 and 5 years postoperatively;Percutane transluminale coronairangioplastiek in 1980/'85 en in 1995/'96: Vaker meervatslijden, minder heringrepen en ongewijzigde sterfte 1 en 5 jaar na de ingreep

Nederlands Tijdschrift voor Geneeskunde

Volumn 146, Issue 46, 2002, Pages 2196-2200

  Van Domburg, R T ^a   Vos, J ^a   Serruys, P W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; FOLLOW UP; HEART EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MORTALITY; PREDICTION; REOPERATION; STENT; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR DISEASE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMORBIDITY; CORONARY ARTERY BYPASS; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REOPERATION; RISK FACTORS; SEX FACTORS; STENTS; SURVIVAL ANALYSIS;

EID: 0037121379     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Gruentzig AR, King 3rd SB, Schlumpf M, Siegenthaler W. Longterm follow-up after percutaneous transluminal coronary angioplasty. The early Zurich experience. N Engl J Med 1987;316: 1127-32.
2. Serruys PW, Jaegere P de, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95.
3. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501.
4. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
5. Domburg RT van, Foley DP, Feyter PJ de, Giessen W van der, Brand MJ van den, Serruys PW. Long-term clinical outcome after coronary balloon angioplasty: Identification of a population at low risk of recurrent events during 17 years of follow-up. Eur Heart J 2001;22:934-41.
6. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition of Prevention of Ischemic Complication. JAMA 1997;278:479-84.
7. Hamm CW, Heeschen C, Goldmann B, Vahanian A, Adgey J, Miguel CM, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999;340:1623-9.
8. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al. RAVEL Study Group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773-80.